Who are Imprimis Dropless's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imprimis-dropless.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Imprimis Dropless — Competitive Intelligence Brief

Imprimis Dropless (Imprimis Dropless) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Compounded ophthalmic anti-inflammatory and antimicrobial combination. Area: Ophthalmology.

marketed Compounded ophthalmic anti-inflammatory and antimicrobial combination Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Imprimis Dropless (Imprimis Dropless) — Eye Center of North Florida. Imprimis Dropless is a compounded ophthalmic formulation combining multiple anti-inflammatory and antimicrobial agents to prevent infection and inflammation following cataract surgery without requiring separate post-operative eye drops.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Imprimis Dropless TARGET	Imprimis Dropless	Eye Center of North Florida	marketed	Compounded ophthalmic anti-inflammatory and antimicrobial combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Compounded ophthalmic anti-inflammatory and antimicrobial combination class)

Eye Center of North Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imprimis Dropless — Competitive Intelligence Brief. https://druglandscape.com/ci/imprimis-dropless. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab